三生制药创新合作释放增长潜力:双抗授权与核心品种驱动未来业绩

报告大厅
May 21, 2025

中国报告大厅网讯,2025年开年以来,全球生物医药行业加速资源整合与技术突破,头部企业通过管线布局和国际合作持续巩固竞争优势。近日,三生制药在肿瘤免疫领域取得重要进展,其PD-1/VEGF双特异性抗体(SSGJ-707)的全球权益合作引发市场关注,叠加核心产品特比澳的稳健增长与丰富研发管线支撑,公司正加速进入创新驱动发展的新阶段。  一、全球权益合作释放业绩弹性  中国报告大厅发布的《2025-...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10